On Tuesday, Nukkleus hit an important technical milestone, with its Relative Strength (RS) Rating entering into the 90-plus percentile with an upgrade to 93, up from 87 the day before.
How To Use Stock Charts To Stay Profitable And Protected
IBD's unique RS Rating identifies technical performance by using a 1 (worst) to 99 (best) score that identifies how a stock's price performance over the last 52 weeks matches up against the rest of the market.
Over 100 years of market history reveals that the best stocks often have an RS Rating of above 80 as they launch their biggest runs.
While the stock is not near an ideal entry right now, see if it goes on to form and break out of a proper consolidation.
The company posted 0% earnings growth last quarter, while sales growth came in at -100%.
Nukkleus earns the No. 19 rank among its peers in the Computer Software-Financial industry group. Nayax, Guidewire Software and CoreCard are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
